AstraZeneca and Circassia Partnering on COPD Inhalants
AstraZeneca and Circassia are partnering to develop and commercialize two inhaled respiratory treatments for chronic obstructive pulmonary disease (COPD) in the United States, Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide). Tudorza was approved by the U.S. Food and Drug Administration (FDA) in 2012, and its marketing began that…